Denovo Biopharma LLC, of San Diego, said it exclusively licensed pomaglumetad methionil, a late-stage mGlu2/3 receptor agonist, from Eli Lilly and Co., of Indianapolis, gaining all rights to develop, manufacture and commercialize the drug globally, including transfer of all intellectual property and other rights, data and information.